Cartography Biosciences Inc. has closed a $67 million series B financing to support its pipeline of T-cell engaging bispecific and multispecific antibody therapeutics that target novel and highly specific tumor antigens.

Cirrus Therapeutics Inc. has closed an $11 million seed financing to advance its pipeline of gene and cell therapies designed to preserve sight and extend ocular healthspan in patients with chronic blinding diseases.

Pop Biotechnologies Inc. has been awarded a $2.46 million grant by the National Institutes of Health (NIH) to pursue development of a ‘mosaic’ active immunotherapy against Alzheimer’s disease.

Convatec Group plc plans to invest more than $1 billion in the U.S. and U.K. over the next decade as it looks to accelerate its research and development (R&D) ambitions.

Full-Life Technologies Ltd. announced Sept. 29 the completion of a $77 million financing, comprising $50 million in series C equity and $27 million in debt financing, which will be used to advance a portfolio of radiopharmaceuticals and radionuclide-drug conjugates worldwide.